Mountain High Acquisitions Corp (OTCMKTS:MYHI) was at $0.210, showing a -1.41% decrease. Around 273,551.00 shares have been traded, versus an-average trading volume of 684,176.00 shares.
Mountain High Acquisitions Corp. focuses on the commercial hemp and CBD products industries. The company is based in Scottsdale, Arizona.
Earth Science Tech Inc (OTCMKTS:ETST) was trading lower by -1.18% to $1.68. So far, around 12,889.00 shares have changed hands in this session. After opening at $1.70, the stock hit as high as $3.95. However, it traded between $1.60 and $1.70 over the last twelve months.
On March 9, 2017 Earth Science Tech, Inc. (ETST), an innovative biotech company focused on cannabis (industrial hemp) and cannabinoid research and development, nutraceuticals, pharmaceuticals, and medical devices, is pleased to announce it has formulated a new Cannabis CBD-based pre-workout sports supplement with Forzagen. Additionally, the company’s joint venture with Karmavore Superfoods is off to a good start, and their chocolates (infused with ETST CBD) are selling well.
The company recently announced a joint venture with Nutrition Specialties and Forzagen, (Earth Science Tech, Enters Multi-Billion Dollar Sports Supplement Industry via Joint Venture with Nutrition Specialties and Forzagen) where Earth Science Tech and Forzagen will formulate new CBD-based sports products. Earth Science Tech will help develop the market in the United States while Forzagen will develop the market in Mexico and other international accounts. Earth Science Tech, together with Forzagen, have formulated a full-spectrum CBD-based pre-workout supplement called Black Demon 2.0. The supplement was formulated for serious athletes, and is incredibly potent. Forzagen and Earth Science Tech will be splitting both the costs and revenues of Black Demon 2.0, and it is currently in the label design phase. It is expected to be bottled and start selling within Q2 or Q3 of 2017.
Nemus Bioscience Inc (OTCMKTS:NMUS) shares today, losing -9.65 per cent to $0.280. Around 168,612.00 shares changed hands so far in this session compared to an-average trading volume of 306,555.00 shares.
Nemus Bioscience Inc (NMUS) on March 22, 2017 announced that bactericidal synergy was achieved against multiple species of methicillin-resistant Staphylococcus aureus (MRSA) utilizing a proprietary cannabinoid-based therapeutic platform. MRSA species tested included community acquired- (CA-MRSA), healthcare-acquired- (HA-MRSA), and mupirocin-resistant (MR-MRSA) strains of MRSA.
In vitro studies demonstrated that when using unique strategic cannabinoid-based cocktails, fractional-inhibitory concentration (FIC) levels demonstrating synergy between mixtures of individual cannabinoid-based components ranged from 0.06 to 0.28. FIC findings below 0.5 indicate significant killing potential of the mixture.
“This work highlights the importance of Nemus’ relationship with the University which has significant experience and intellectual capital related to cannabinoid chemistry and physiology, dating back to 1968,” stated Brian Murphy, M.D., C.E.O. and Chief Medical Officer of Nemus. “These unique botanically derived components establish an anti-infective platform which could potentially be expanded into other types of bacteria, as well as viruses, and fungi.”